cefadroxil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
antibiotics, cefalosporanic acid derivatives	526	50370-12-2

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: cefadroxil cefadrox cephadroxil cefadroxil hemihydrate	Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative. Molecular weight: 363.39 Formula: C16H17N3O5S CLOGP: -2.51 LIPINSKI: 0 HAC: 8 HDO: 4 TPSA: 132.96 ALOGS: -2.96 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

cefadroxil
cefadrox
cephadroxil
cefadroxil hemihydrate

Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.

Molecular weight: 363.39
Formula: C16H17N3O5S
CLOGP: -2.51
LIPINSKI: 0
HAC: 8
HDO: 4
TPSA: 132.96
ALOGS: -2.96
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
2	g	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Benet LZ, Broccatelli F, Oprea TI
S (Water solubility)	14.20 mg/mL	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	93 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	78.62 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	95 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution)	0.23 L/kg	Lombardo F, Berellini G, Obach RS
CL (Clearance)	2.50 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.39 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	1.10 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Feb. 17, 1978	FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cross sensitivity reaction	406.20	23.76	69	1778	1900	50601377
Type IV hypersensitivity reaction	253.80	23.76	48	1799	2434	50600843
Rash maculo-papular	121.39	23.76	43	1804	26598	50576679
Oedema	62.01	23.76	36	1811	70145	50533132
Drug hypersensitivity	58.85	23.76	58	1789	250952	50352325
Veillonella infection	27.87	23.76	4	1843	34	50603243
Cellulitis	27.80	23.76	22	1825	70776	50532501
Neisseria infection	27.38	23.76	4	1843	39	50603238
Drug reaction with eosinophilia and systemic symptoms	26.16	23.76	15	1832	28409	50574868
Stomatococcal infection	24.38	23.76	4	1843	87	50603190

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cross sensitivity reaction	183.14	27.61	30	563	1232	29572702

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Cross sensitivity reaction	572.96	23.57	99	2092	3268	64493273
Type IV hypersensitivity reaction	266.11	23.57	52	2139	3370	64493171
Rash maculo-papular	103.91	23.57	44	2147	46982	64449559
Oedema	65.44	23.57	40	2151	91895	64404646
Drug hypersensitivity	45.98	23.57	48	2143	237767	64258774
Drug reaction with eosinophilia and systemic symptoms	44.81	23.57	26	2165	54191	64442350
Toxic epidermal necrolysis	36.60	23.57	20	2171	37146	64459395
Anaphylactic reaction	32.07	23.57	23	2168	68641	64427900
Veillonella infection	27.40	23.57	4	2187	42	64496499
Neisseria infection	25.83	23.57	4	2187	64	64496477
Erythema	24.62	23.57	31	2160	187039	64309502

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	J01DB05	ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS First-generation cephalosporins
CHEBI has role	CHEBI:36047	antibacterial drugs
MeSH PA	D000900	Anti-Bacterial Agents
MeSH PA	D000890	Anti-Infective Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Infection of skin AND/OR subcutaneous tissue	indication	19824006
Streptococcal tonsillitis	indication	41582007
Klebsiella cystitis	indication	60867007
Urinary tract infectious disease	indication	68566005
Tonsillitis	indication	90176007	DOID:10456
Escherichia coli urinary tract infection	indication	301011002
Proteus urinary tract infection	indication	301012009
Streptococcus pyogenes infection	indication	302809008
Infection due to Staphylococcus aureus	indication	406602003
Prevention of Bacterial Endocarditis	off-label use
Impaired renal function disorder	contraindication	197663003
Pseudomembranous enterocolitis	contraindication	397683000

🐶 Veterinary Drug Use

Species	Use	Relation
Cats	Skin and soft tissue infections caused by susceptible strains of Staphylococcus aureus	Indication
Cats	Genitourinary tract infections caused by Escherichia coli	Indication
Cats	Genitourinary tract infections caused by Proteus species	Indication
Cats	Genitourinary tract infections caused by Staphylococcus aureus	Indication
Cats	Skin and soft tissue infections caused by Pasteurella multocida	Indication
Cats	Skin and soft tissue infections caused by Staphylococcus epidermidis	Indication
Cats	Skin and soft tissue infections caused by Streptococcus species	Indication
Dogs	Skin and soft tissue infections caused by Staphylococcus aureus	Indication
Dogs	Genitourinary tract infections caused by Escherichia coli	Indication
Dogs	Genitourinary tract infections caused by Proteus species	Indication
Dogs	Genitourinary tract infections caused by Staphylococcus aureus	Indication

🐶 Veterinary products

Product	Applicant	Ingredients
Cefa-Tabs	HQ Specialty Pharma Corp.	1
Cefa-Drops	HQ Specialty Pharma Corp.	1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.77	acidic
pKa2	9.72	acidic
pKa3	13.53	acidic
pKa4	7.63	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Solute carrier family 15 member 1	Transporter	P46059	S15A1_HUMAN		Ki	2.14		WOMBAT-PK
Bacterial penicillin-binding protein	Enzyme		PBPA_ECOLI PBPB_ECOLI DACC_ECOLI PBP2_ECOLI FTSI_ECOLI DACA_ECOLI DACB_ECOLI	INHIBITOR				CHEMBL	CHEMBL

External reference:

ID	Source
4018151	VUID
N0000146488	NUI
D00257	KEGG_DRUG
119922-85-9	SECONDARY_CAS_RN
1297878	RXNORM
4018151	VANDF
C0007538	UMLSCUI
CHEBI:53667	CHEBI
CHEMBL1644	ChEMBL_ID
DB01140	DRUGBANK_ID
D002434	MESH_DESCRIPTOR_UI
47965	PUBCHEM_CID
4831	IUPHAR_LIGAND_ID
280111G160	UNII
d00080	MMSL
004959	NDDF
13414000	SNOMEDCT_US
372651006	SNOMEDCT_US
66592-87-8	SECONDARY_CAS_RN

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3196	CAPSULE	500 mg	ORAL	ANDA	22 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3196	CAPSULE	500 mg	ORAL	ANDA	22 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	0093-4059	TABLET	1000 mg	ORAL	ANDA	23 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9766	POWDER, FOR SUSPENSION	500 mg	ORAL	ANDA	21 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9767	POWDER, FOR SUSPENSION	250 mg	ORAL	ANDA	21 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9947	CAPSULE	500 mg	ORAL	ANDA	21 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	0143-9948	TABLET, FILM COATED	1 g	ORAL	ANDA	23 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	10544-135	CAPSULE	500 mg	ORAL	ANDA	19 sections
CEFADROXIL	Human Prescription Drug Label	1	16590-043	CAPSULE	500 mg	ORAL	ANDA	23 sections
Cefadroxil	Human Prescription Drug Label	1	16714-388	CAPSULE	500 mg	ORAL	ANDA	21 sections
Cefadroxil	Human Prescription Drug Label	1	16714-389	POWDER, FOR SUSPENSION	250 mg	ORAL	ANDA	21 sections
Cefadroxil	Human Prescription Drug Label	1	16714-390	POWDER, FOR SUSPENSION	500 mg	ORAL	ANDA	21 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	21695-427	CAPSULE	500 mg	ORAL	ANDA	22 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	33261-018	CAPSULE	500 mg	ORAL	ANDA	19 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	42254-146	CAPSULE	500 mg	ORAL	ANDA	19 sections
CEFADROXIL	Human Prescription Drug Label	1	42549-504	CAPSULE	500 mg	ORAL	ANDA	23 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-553	CAPSULE	500 mg	ORAL	ANDA	19 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-553	CAPSULE	500 mg	ORAL	ANDA	19 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	43063-595	CAPSULE	500 mg	ORAL	ANDA	21 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	45865-503	CAPSULE	500 mg	ORAL	ANDA	19 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	50090-0580	CAPSULE	500 mg	ORAL	ANDA	19 sections
Cefadroxil	Human Prescription Drug Label	1	50090-1915	CAPSULE	500 mg	ORAL	ANDA	21 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	52959-428	CAPSULE	500 mg	ORAL	ANDA	19 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	53002-2290	CAPSULE	500 mg	ORAL	ANDA	19 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	54868-3742	CAPSULE	500 mg	ORAL	ANDA	13 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5693	POWDER, FOR SUSPENSION	250 mg	ORAL	ANDA	14 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5694	POWDER, FOR SUSPENSION	500 mg	ORAL	ANDA	14 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	55289-589	CAPSULE	500 mg	ORAL	ANDA	22 sections
Cefadroxil	HUMAN PRESCRIPTION DRUG LABEL	1	55289-589	CAPSULE	500 mg	ORAL	ANDA	22 sections
Cefadroxil	Human Prescription Drug Label	1	57237-096	CAPSULE	500 mg	ORAL	ANDA	21 sections